Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants with obesity, defined as a Body Mass Index greater than or equal to 30.0 kg/m2
Stable body weight, defined as \<5 kg change (per participant report) for 90 days before visit 1
You may not be if
Any condition possibly affecting drug absorption
Current or prior diagnosis of Type 1 or Type 2 diabetes mellitus or secondary forms of diabetes
History of myocardial infarction, unstable angina, arterial revascularization, stroke, heart failure, or transient ischemic attack within 6 months prior to visit 1
Any malignancy not considered cured
Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 or suspected MTC
History of acute pancreatitis within 180 days (6 months) prior to visit 1 or any history of chronic pancreatitis
Symptomatic gallbladder disease
Medical history or characteristics suggestive of genetic or syndromic obesity or obesity induced by other endocrinological disorders
History of major depressive disorder or other severe psychiatric disorders within the last 2 years
Any lifetime history of a suicide attempt
Known medical history of active liver disease, including chronic active hepatitis B or C, or primary biliary cirrhosis
Known history of HIV
Supine blood pressure greater than or equal to 160 mmHg (systolic) or greater than or equal to 100 mmHg (diastolic)
Clinically relevant ECG abnormalities
Positive urine drug screen
Participation in a formal weight reduction program within 90 days prior to visit 1
Clareo Health | A Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Obesity
